Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (1604)	10/28/1998 1:55:00 AM
From: Maurice Winn	Read Replies (2) \| Respond to of 1762

Hi AJ, thanks for the comments. Both Rituxan and Y2B8 definitely attach to the same CD20 antigen and there are only so many of these antigens on the surfaces of a tumour accessible to the blood stream, so the Y2B9 will definitely be competing for space, looking for some spare antigens to hang on to. And therefore antagonistic, though I think 'antagonistic' in the context of drug cocktails doesn't have quite that meaning. There is a lot more I don't know than do know, so perhaps somebody who has fewer vacancies available for tenancy can tell us. I doubt that the Y2B8 protocol used would enter the realm of unethical because the patient would have first undergone the traditional treatments, which are no longer being effective, then they use the Rituxan treatment. Which is now traditional too, at least since last December. They are then offered the Y2B8 as an additional treatment still. I think quite ethically because it isn't taking anything that might help away from the person, but offering them something extra, which obviously does help, with relatively small additional hazards. The hazards are large enough that innocent bystanders keep well clear of the radioactive Yttrium, just as they avoid contamination with cyclophosphamide, so it is not exactly benign. For intermediate grade, ditch the Rituxan and go straight to Y2B8/Oncolym/TNT say I! Regards, Maurice